Asunercept (APG101) is a Selective CD95L Inhibitor for Glioblastoma Research
Glioblastoma is the most frequent and aggressive form of brain tumour. Significantly, the highly invasive growth of these tumors often prevents complete surgical resection. Consequently, patients progress shortly after surgery. In fact, clinical evidence confirms CD95L as a promising novel target for the treatment of recurrent glioblastoma and potentially...
SB-332235 is an Orally Active CXCR2 Antagonist
Chemokines are low m.w. proteins that modulate the immune response through the chemoattraction and activation of leukocytes. These mediators have four classes. Chemokines in which the first two cysteines are separated by a single, nonconserved amino acid are CXC or chemokines, while those containing adjacent N-terminalcysteine residues are CC ...